Skip to main content
Clinical Trials/NCT05957666
NCT05957666
Recruiting
Phase 2

Comparison of Oral Versus Vaginal Misoprostol for Labour Induction at Term

Services Institute of Medical Sciences, Pakistan1 site in 1 country176 target enrollmentJune 16, 2023

Overview

Phase
Phase 2
Intervention
Misoprostol Oral Tablet
Conditions
Induction of Labour With Misoprostol
Sponsor
Services Institute of Medical Sciences, Pakistan
Enrollment
176
Locations
1
Primary Endpoint
vaginal birth
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

A randomised control trial to compare oral and vaginal misoprostol for induction of labour in term patients.The objective is to determine whether use of standardised vaginal misoprostol regimen will result in decreased cesaerean section rate among women with bishop score of lessthan or equal to 6 who require induction of labpour at term compared to oral misoprostol regimen.

Detailed Description

The objective of study is to determine whether the use of standardised vaginal misoprostol regimen will result in decreased cesaerean section rate among women with bishop score of less than or equal to 6 who require induction of labour at term compared to oral misoprostol regimen.It is a randomised control trial conducted in department of obs and gynae unit 1 from june 2023. Total 176 patients are included in this study and they will be randomised by envelope method to recieve either oral or vaginal misoprostol in a dose of 50microgram.In both groupds dose will be repeated after 6 hours if required.Maximum 2 doses will be given.patients will be monitored for uterine contractions and fetal hearts.Vaginal examination will be done at 4hours and 8 hours following misoprostol dose or earlier if patient complains of leaking and labour pains.Membranes will be ruptured once cervical dilatation is greater than 3cm.in absence of adequate uterine contractions oxytocin infusion will be started.Fetal hearts will be monitored every 30 minutes from time of induction.Progress of labour will be assessed through partogram.

Registry
clinicaltrials.gov
Start Date
June 16, 2023
End Date
December 16, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Services Institute of Medical Sciences, Pakistan
Responsible Party
Principal Investigator
Principal Investigator

Tayyiba Wasim

Professor Obstetrics and Gynaecology

Services Institute of Medical Sciences, Pakistan

Eligibility Criteria

Inclusion Criteria

  • Cephalic presentation Prelabour rupture of membranes Singleton pregnancies reaching 41 weeks G1 to G4 Bishop score of less than or equal to 6 Medical disorders(GDM,PIH) -

Exclusion Criteria

  • Previous uterine scar Antepartum hemorrhage Cephalopelvic disproportion Multiple gestation Multiparity Oligohydramnios/polyhydramnios IUGR Severe systemic illness like pre eclampsia,eclampsia,cardiac,hepatic,renal disease PPROM

Arms & Interventions

oral misoprostol

oral misoprostol will be given in a dose of 50microgram and repeated after 6 hours if required.Maximum 2 doses will be given

Intervention: Misoprostol Oral Tablet

vaginal misoprostol

vaginal misoprostol will be given in a dose of 50 microgram and repeated after 6 hours if required.Maximum 2 doses will be given

Intervention: vaginal misoprostol

Outcomes

Primary Outcomes

vaginal birth

Time Frame: vaginal birth within 24 hours of admission

vaginal birth within 24 hours of admission with 2 doses of misoprostol given 6 hours apart

Secondary Outcomes

  • induction to delivery interval(within 24 hours)
  • cesaerean section(within 24 hours)
  • uterine hyperstimulation(more than 10 cotractions in every 10 minutes)
  • fetal distress(within 24 hours)

Study Sites (1)

Loading locations...

Similar Trials